Lengthy Process Of Biologic Approval And Administration Delays Treatment Of Patients With Moderate-To-Severe Asthma

Esha Sehanobish,Kenny Ye,Karim Sariahmed,Joshua Kurian,Jalpa Patel,Daniel Belletti,Yen Chung,Sunit Jariwala,Andrew White,Elina Jerschow

The Journal of Allergy and Clinical Immunology（2022）

引用 0|浏览1

暂无评分

摘要

Monoclonal antibodies (biologics) are indicated in patients with poorly controlled moderate-to-severe asthma. The process of application, approval, and administration of a biologic places a large administrative burden on clinical teams. In this study, we analyzed the biologic approval process at two US centers.

查看译文

关键词

biologic approval,administration delays treatment,lengthy process,patients,moderate-to-severe

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要